Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Matthew Perraton GBM Update from Jan 2 email
View:
Post by Eoganacht on Jan 12, 2024 11:08pm

Matthew Perraton GBM Update from Jan 2 email

Theralase® Non-GLP Toxicity Analysis for Brain Cancer
 
Theralase® is forwarding a summary of the preclinical data to Health Canada for review and response on a GLP toxicology program to be completed by the Company by Q1 2024.
 
Based on the successful completion of the GLP toxicology program, Theralase® intends to commence a Phase Ia/Ib dose escalating clinical study in 2024 in patients diagnosed with GBM to determine the appropriate clinical dose of the drug from both a toxicity and tumor localization perspective. 
 
This phase will also look at radiation activation of a single IV dose of Rutherrin®.
 
Following the successful completion of the Phase Ia/Ib clinical study, Theralase® plans to commence a Phase IIa/IIb clinical study in Canada and the United States focused on enrolling and treating patients diagnosed with recurrent GBM, with multiple radiation activated doses of Rutherrin®.
Comment by DJDawg on Jan 13, 2024 9:48am
Thanks for posting Eog. There is some very interesting stuff here. For those that are not aware the way you evaluate solid tumours is different that non-solid and bladder. It all comes down to special criteria called RECIST. You treat and then you calculate any drop in size of the mass (GBM here) and a certain amount is considered real. With a lot of newer cancer agents, you take a drug regularly ...more  
Comment by Longholder99 on Jan 13, 2024 12:36pm
Great info Dawg and Eog.  Thanks 
Comment by Eoganacht on Jan 13, 2024 5:21pm
Very interesting post Dawg. It may be that all that can be hoped for is to give GBM patients more time before they succumb to the disease. It's a horrific prognosis. Adult GBM patients treated with chemo and radiation have a median survival of 14.6 months and a 2 year survival rate of 30%. But we really don't know how effective repeated treatments activating systemically administered ...more  
Comment by patience69 on Jan 13, 2024 5:36pm
Amazing posts & topics guys. I am the biggest bull going but the million dollar question remains. Where & when do we get the money to pursue it. I think that it is fair to say that this has been discussed for years (2017 news release ) however to the best of my knowledge money has held us back. Are we confident that this is changing soon? Lets hope
Comment by fecats on Jan 13, 2024 9:44pm
At the end of the day everything in this world comes down to money. We simply don't have enough to move anything else forward. I think we are far enough along on NMIBC that we should be able to attract  money in a different way than just pp. I trust mgmt is exploring other ways to raise money such as a JV or royalty deal . I am confident we have enough to be attractive at this point ...more  
Comment by Oilminerdeluxe on Jan 14, 2024 2:23am
No doubt, they are exploring other ways of finding money. But it would be much easier with BTD in hand. I suspect that any deal would require many, many months to negotiate. Maybe that has been going on, but how strong could their hand be? BTD should at least make it stronger. Timewise, it could be grueling long to wait still if those supposed negotiations have not started for real with interested ...more  
Comment by Alamir1111 on Jan 13, 2024 5:38pm
Interesting is that tlt is collaborating more with HC getting response and approval like third dosing for nmibc now gbm.like it
Comment by Oilminerdeluxe on Jan 13, 2024 1:47pm
Having two studies going would be sweet. Should boost us. With a little luck, the pre-Btd could be sent in by now
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250